Horizons ETFs Rebalances Marijuana-Focused ETFs

Horizons ETFs Management (Canada) Inc. (“Horizons ETFs”) has completed the quarterly rebalance of the constituent holdings of the Horizons Marijuana Life Sciences Index ETF (“HMMJ”:TSX), the Horizons US Marijuana Index ETF (“HMUS”:NEO) and the Horizons Emerging Marijuana Growers Index ETF (“HMJR”:NEO).
Stock Symbols

Robbins Arroyo LLP: Corbus Pharmaceuticals Holdings, Inc. (CRBP) Sued for Misleading Shareholders

Shareholder rights law firm Robbins Arroyo LLP reminds shareholders that purchasers of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) filed a class action complaint against the company for alleged violations of the Securities and Exchange Act of 1934 between November 14, 2016 and February 28, 2019. Corbus purports to be a pharmaceutical company focused on the development and commercialization of novel therapies to treat inflammatory and fibrotic diseases.
Stock Symbols

Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in June

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company focused on treating inflammatory and fibrotic diseases by targeting the endocannabinoid system, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present at two upcoming investor conferences in June.
Stock Symbols

Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in May

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company focused on treating inflammatory and fibrotic diseases by targeting the endocannabinoid system, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present at two upcoming investor conferences in May.
Stock Symbols

CRBP, NIO & CORT Deadline Alert – Bronstein, Gewirtz & Grossman, LLC Class Action

Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Stock Symbols

CLASS ACTION UPDATE for T, CNDT, CRBP and BSX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.
Stock Symbols

CRBP MAY 13th DEADLINE: Rosen Law Firm Reminds Corbus Pharmaceuticals Holdings, Inc. Investors of Important Deadline in Securities Class Action; Investors with Losses in Excess of $100K are Encouraged to Contact the Firm – CRBP

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Corbus Pharmaceuticals Holdings, Inc. from November 14, 2016 through February 28, 2019, inclusive (the “Class Period”) of the important May 13, 2019 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Corbus investors under the federal securities laws.
Stock Symbols

Corbus Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2019 Operational and Financial Results on May 9, 2019

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company focused on treating inflammatory and fibrotic diseases by targeting the endocannabinoid system, today announced that the Company will host a conference call and live audio webcast on Thursday, May 9, 2019 at 8:30 a.m. ET to discuss operational and financial results for the quarter ended March 31, 2019 and provide a corporate update.
Stock Symbols